CXCR4 and diabetes mellitus: Although not specifically tested in DM, a selective CXCR4 antagonist AMD3465 decreased mineralocorticoid-dependent renal fibrosis in mice [274] and targeting CXCR4 prevented glomerular injury associated to high podocyte CXCR4 expression in mice [275].